16 September 2026 editorial review · Trial
Next-generation Omnipod M/S AID algorithms in T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: No additional discrepancy identified in the reviewed summary/design/endpoint and eligibility fields. Existing sponsor or historical claims are not all independently certified by this protocol comparison.
Registry: NCT07593625. Endpoint reviewed: Percentage of time <54 mg/dL (72-hour Omnipod M Hotel Period); Percentage of time <70 mg/dL (72-hour Omnipod M Hotel Period); Percentage of time >180 mg/dL (72-hour Omnipod M Hotel Period); Percentage of time <54 mg/dL (4-week Omnipod M outpatient); Percentage of time <54 mg/dL (Final 3 weeks of Omnipod S outpatient); Percentage of time <70 mg/dL (4-week Omnipod M outpatient); Percentage of time <70 mg/dL (Final 3-weeks Omnipod S outpatient); Percentage of time >180 mg/dL (4-week Omnipod M outpatient); Percentage of time >180 mg/dL (Final 3-weeks Omnipod S outpatient). Eligibility reviewed: Age 2 Years to 70 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Literature access limit: No usable primary abstract was independently recovered for this record in this pass. Current registry protocol was the main source; detailed sponsor or conference data remain dependent on the cited source and were not fully reverified.